Impact of scalp nerve block on recovery quality after brain tumor surgery

Effect of Scalp Nerve Block on the Quality of Recovery in Patients Undergoing Supratentorial Tumor Resection

Not applicable Interventional Second Affiliated Hospital, School of Medicine, Zhejiang University · NCT06157359

This study is trying to see if a scalp nerve block can help people recover better after brain surgery for tumors compared to standard care.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment84 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University Academic / other
Locations1 site (Hangzhou, Zhejiang)
Trial IDNCT06157359 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effect of a scalp nerve block (SNB) on the quality of recovery (QoR) in patients undergoing craniotomy for supratentorial tumors. A total of 84 patients will be randomly assigned to receive either the SNB or standard care, with the primary outcome being the QoR score measured 24 hours post-surgery. Secondary outcomes will include additional QoR scores, sedation levels, and various perioperative metrics such as opioid consumption and recovery duration. The goal is to determine if SNB can improve postoperative recovery in this patient population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 65 diagnosed with a supratentorial tumor scheduled for elective craniotomy.

Not a fit: Patients with extreme BMI, severe comorbidities, or specific tumor characteristics may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly enhance postoperative recovery and pain management for patients undergoing brain surgery.

How similar studies have performed: Previous studies have shown promising results with scalp nerve blocks in similar surgical contexts, suggesting potential for success in this trial.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age between 18 and 65;
* the diagnosis was supratentorial tumor;
* scheduled for elective supratentorial craniotomy with general anesthesia ;
* the American Society of Anesthesiologists physical status I-III;

Exclusion Criteria:

* the BMI≦18kg/m2 or BMI≧30kg/m2;
* refusing to sign written informed consent;
* anticipated surgery duration is too short (\<2 h) or too long (\>6 h);
* liver or kidney dysfunction, severe cardiopulmonary failure or nervous system disease ;
* with other malignancies ;
* severe hematological disease and / or abnormal coagulation function;
* fever, systemic and / or scalp infection;
* tumors are metastases, aneurysms, hemangioma, or located in the skull base, or located in functional brain areas such as language and movement;
* allergy to any drug used in this study;
* a history of craniotomy tumor resection;
* preoperative usage of antiinflammatory agents or analgesics;
* pregnant women, lactating women, illiterate people, people with cognitive impairment, a history of mental illness, unable to communicate and complete the scale assessment;
* patients with severe hemodynamic disturbances or other life-threatening complications during the operation, or those transferred to the intensive care unit (ICU) after surgery.

Where this trial is running

Hangzhou, Zhejiang

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Postoperative AnalgesiaQuality of RecoverySupratentorial TumorCraniotomyScalp Nerve BlockSupratentorial tumor resectionScalp nerve blockquality of recovery
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.